US-based Pfizer can now ramp up development efforts for its combination treatment against non-alcoholic steatohepatitis (NASH) with liver fibrosis, a type of non-alcoholic fatty liver disease, as the US Food and Drug Administration (FDA) has decided to fast-track the firm’s treatment candidate, Pfizer has announced in a press release.
The fast-track designation grants Pfizer more frequent meetings with US health authorities, cutting overall case processing for the drug, which is built on two enzymes: ervogastrat and clesacostat.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Covid vaccine race lights fire under GSK boss as RSV battle intensifies
GSK Plc is planning to launch a Covid shot that comes almost two years after Pfizer Inc. took the world by storm. For Phil Dormitzer, it’s a reminder of why he was hired at the UK drugmaker: to help return its immunization business to the top after it stumbled during the pandemic.
Bavarian Nordic to supply US with additional 2.5 million monkeypox vaccines
The deliveries will start in the fourth quarter of 2022 and continue into 2023, when the majority of the doses will be provided.
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
QA Senior Specialist 
Commercial Market Data Manager 
Project Mgr for Medical Device Development 
Principal Scientist – Pharmacology 
Biomarker Operations Lead 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Medical Advisor 
KLIFO is looking for a Project Director for our office in Denmark or Germany or Sweden 
Director Regulatory Affairs 
Nordic Medical Advisor 
Project Managers keep all of us healthy 
Regulatory Affairs Manager - Maternity Cover